PRODUCT LIFE
Acquired by
21 INVEST / OAKLEY CAPITAL INVESTMENTS
PRODUCT LIFE acquired by 21 INVEST / OAKLEY CAPITAL INVESTMENTS
Target
PRODUCT LIFE
Acquirer
21 INVEST / OAKLEY CAPITAL INVESTMENTS
Context
21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest. The strategic roadmap was focused on transforming PLG into an undisputed global leader through massive international consolidation.
The transaction values PRODUCT LIFE at an EV/Revenue multiple of LOGIN.
This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
ProductLife Group (PLG) is a specialized global provider of outsourcing and consulting services for the pharmaceutical and life sciences industries. The company focuses on the highly regulated segments of Regulatory Affairs and Pharmacovigilance, supporting drug manufacturers through the entire product lifecycle—from clinical development to market authorization and post-market safety monitoring.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with PRODUCT LIFE
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.